Roche to take $1.6 billion charge to close sites in Europe, U.S.
Reuters
Published Nov 12, 2015 12:44PM ET
Roche to take $1.6 billion charge to close sites in Europe, U.S.
ZURICH (Reuters) - Roche (VX:ROG) is to stop manufacturing at four sites in Europe and the United States in a move that could mean up to 1,200 job losses as it addresses "current underutilization" resulting from a changing portfolio of medications.
The Swiss drugmaker's move, to result in restructuring charges of 1.6 billion Swiss francs ($1.6 billion) through 2021, affects locations in Clarecastle, Ireland; Leganes, Spain; Segrate, Italy; and Florence in the United States.
Up to 600 million francs of the charges will be in cash, the company said in a statement on Thursday. It said estimated non-core costs in 2015 are up to 800 million francs, with only a minor cash flow impact for the current year.
Roche said its newer specialized medicines require innovative manufacturing technologies and will be produced in smaller volumes. As a result, it no longer needs the four sites.
Daniel O'Day, chief operating officer of Roche's Pharmaceuticals Division, said the company is hoping to sell the plants, in a bid to reduce job losses.
"We are aware of the impact this decision has on our colleagues, and we will do our utmost to support them during this transition," he said.
Additionally, Roche will spend 300 million francs to strengthen development and launch capabilities for specialized medicines at Kaiseraugst, in its home country of Switzerland.
Roche has been concentrating activities around its Basel headquarters as part of plans to spend 3 billion francs, including on a research and development center, through 2024.
($1 = 1.0010 Swiss francs)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.